Poster Presentations: Wednesday, October 26, 2011 |

Adherence to Phosphodiesterase Type 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension - A Real-World Analysis FREE TO VIEW

Aaron Waxman, MD; Shih-Yin Chen, PhD; Luke Boulanger, MA; Gil Golden, MD
Chest. 2011;140(4_MeetingAbstracts):736A. doi:10.1378/chest.1114266
Text Size: A A A
Published online


PURPOSE: Pulmonary arterial hypertension (PAH) requires chronic pharmacologic therapy and published adherence data are limited on use of phosphodiesterase type 5 inhibitors (PDE5Is) in clinical practice. This study assessed factors associated with adherence to PDE5Is for the treatment of PAH.

METHODS: We analyzed pharmacy claims from Medco between 01/2008-12/2010. Patients were selected if they had at least one claim for sildenafil or tadalafil (PAH-indicated brands only) between 05/2009-05/2010. Patients naïve to PDE5Is during 12 months prior to the index date (date of first prescription) were included. Patients were considered adherent if their proportion of days covered (PDC) was ≥80% over a six month period. Logistic regressions were estimated to assess factors associated with adherence. Analyses were performed stratified by use of a specialty pharmacy (SP) or retail pharmacy (RP).

RESULTS: The study included 2,143 patients (mean age: 65 years; 65% female), of which 1,817 were prescribed sildenafil (approved dose 20mg thrice-daily) and 326 were prescribed tadalafil (approved dose 40mg once-daily). Forty-seven percent of patients were adherent to PDE5Is, and adherence was significantly higher among tadalafil (60.7%) than sildenafil users (44.3%, p<0.001). Adherence was higher among 930 SP users (65.6%) than 1,213 RP users (32.3%, p<0.001). Twenty-seven percent of patients received their index prescription from a pulmonologist, 23% from a cardiologist, 17% from primary care provider, and the rest from other or unknown specialty. Among RP users, evaluation of adjusted regressions revealed that factors associated with higher adherence were: use of tadalafil (OR=2.62; 95% CI: 1.61-4.24) and prescription from pulmonologist (OR: 1.68; 95% CI: 1.14-2.47). Similar associations were not observed among SP users.

CONCLUSIONS: In clinical practice, adherence to PDE5Is for PAH is sub-optimal.

CLINICAL IMPLICATIONS: Our findings suggest enhanced adherence to PDE5Is in patients with PAH is associated with simpler dosing frequency, use of SP, and index prescription by a pulmonologist.

DISCLOSURE: Aaron Waxman: Consultant fee, speaker bureau, advisory committee, etc.: Aaron Waxman is an investigator and scientific advisor to United Therapeutics

Shih-Yin Chen: Consultant fee, speaker bureau, advisory committee, etc.: Shih-Yin Chen is an employee of United BioSource Corporation, which was contracted by United Therapeutics to work in collaboration on this study.

Luke Boulanger: Consultant fee, speaker bureau, advisory committee, etc.: Luke Boulanger is an employee of United BioSource Corporation, which was contracted by United Therapeutics to work in collaboration on this study.

Gil Golden: Employee: Gil Golden is an employee of United Therapeutics.

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543